Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment ...
Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naïve and pretreated patients with HER2-mutant advanced NSCLC. The combination of sacituzumab with ...
A patient with breast cancer was able to avoid unnecessary mastectomy through the use of a virtual reality simulation, ...
Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC. The addition of lenvatinib (Lenvima) to ...
Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...
Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...
Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC. The combination of buparlisib and paclitaxel did not show an ...
Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...
A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...
Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback